Barcelona

• A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel … Ended
  2023-509243-27-00 4 2023-04-12 Moderate-to-Severe Uncontrolled Asthma
• A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants with Advanced/Metastatic Non-Sq … Ended
  2022-500608-23-00 4 2023-04-06 Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squ
• A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination w … Ended
  2022-501451-87-00 9 2023-03-31 Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
• INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended
  2022-501505-13-00 1 2023-03-31 Metastatic melanoma
• Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment o … Ended
  2022-500538-27-00 10 2023-03-30 Adjunctive therapy to antidepressants for the treatment of major depr
• Phase 2b Study of GSK4532990 in Adults with NASH (HORIZON) Ended
  2023-507503-62-00 4 2023-03-30 Non-alcoholic Fatty Liver Disease
• A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in … Ended
  2023-510047-37-00 4 2023-03-30 Treatment-resistant depression (TRD)
• A clinical study to evaluate a new medicinal product VS-01 in patients with an acute episode on top of a chronic liver disease (called acute … Ended
  2024-513706-56-00 4 2023-03-22 Acute-on-chronic liver failure (ACLF) is characterized by hepatic and
• A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patien … Ended
  2022-501363-40-00 3 2023-03-17 Advanced or metastatic solid tumors with a KRAS-G12C mutation
• Cook´s balloon versus dinoprostone for Labor Induction of term pregnancies with fetal GROWth restriction (COLIGROW study) Ended
  2024-513523-16-00 5 2023-03-16 Fetal growth restriction
• OMX-0407 Phase I Study Ended
  2024-514554-75-00 1 2023-03-16 Previously treated unresectable solid tumours
• C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended
  2024-513269-37-00 6 2023-03-14 Migraine attacks with or without aura
• C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan … Ended
  2024-513270-21-00 6 2023-03-14 migraine headaches with or without aura
• Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after … Ended
  2024-510980-40-00 3 2023-03-09 Small cell lung cancer
• A study to find out if daridorexant is safe and efficacious to treat insomnia in patients with insomnia and comorbid nocturia Ended
  2022-501246-30-00 6 2023-03-08 Insomnia Disorder
• A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 Ended
  2023-504540-33-00 5 2023-03-06 COVID-19
• Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line o … Ended
  2023-508860-31-00 5 2023-02-28 Stage IV colon or rectal adenocarcinoma (mCRC).
• Study of exposure to substances prohibited by the World Anti-Doping Agency in healthy volunteers. Proof of concept. Ended
  2022-502216-36-00 3 2023-02-27 Healthy volunteers
• A study to evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of treatment in children and adolescents with ASD Ended
  2024-512202-25-00 4 2023-02-27 Irritability associated with autistic disorder in children and adolesc
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients Ended
  2022-501183-17-00 7 2023-02-23 Non-Small Cell Lung Cancer
• Multiple Dose Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of MYK-224 in Participants with Sympto … Ended
  2023-508831-29-00 4 2023-02-15 Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow T
• A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Particip … Ended
  2023-504017-79-00 4 2023-02-14 Treatment of AD dementia
• A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Ended
  2023-504111-33-00 4 2023-02-14 Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or F

Showing 2,905–2,928 of 3,391 trials